Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.56 |
| ▸ | SIGLEC9 | Q9Y336 | 2/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.49 |
| ▸ | C3AR1 | Q16581 | 6/20 | 0.47 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6346302 | 0.89 | NOS2 (0.51) | EPHX2SIGLEC9CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL6355548 | 0.88 | CYP2D6 (0.48) | EPHX2CYP2D6CYP2C9GRIN2BEGLN1 | |
| SCHEMBL6343564 | 0.81 | NOS2 (0.61) | EPHX2GRIN2BEGLN1 | |
| SCHEMBL7368825 | 0.80 | EPHX2 (0.59) | EPHX2CYP3A4CYP2D6CYP2C9GRIN2B | |
| SCHEMBL23013331 | 0.80 | SIGLEC9 (0.57) | EPHX2SIGLEC9CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL23013515 | 0.80 | SIGLEC9 (0.57) | EPHX2SIGLEC9CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL6985709 | 0.79 | SIGLEC9 (0.45) | EPHX2SIGLEC9 | |
| SCHEMBL4836752 | 0.78 | KDM4E (0.54) | C3AR1 | |
| SCHEMBL6987185 | 0.77 | SIGLEC9 (0.45) | EPHX2SIGLEC9C3AR1 | |
| SCHEMBL13039588 | 0.76 | CXCR3 (0.49) | CYP3A4CYP2D6CYP2C9GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6878725-B2 | Serine protease inhibitors | ELI LILLY AND COMPANY (US) | 2005-04-12 | — | — | US | disclosed |
| US-20040242656-A1 | Serine protease inhibitors | LIEBESCHUETZ JOHN WALTER (GB) | 2004-12-02 | — | — | US | disclosed |
| EP-1289950-B1 | SERINE PROTEASE INHIBITORS | LILLY CO ELI (US) | 2004-09-08 | — | — | EP | disclosed |
| US-20030078438-A1 | Serine protease inhibitors | ELI LILLY AND COMPANY | 2003-04-24 | — | — | US | disclosed |
| EP-1289950-A1 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2003-03-12 | — | — | EP | disclosed |
| WO-2001096296-A1 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078438-A1 | Serine protease inhibitors | HPN, LPXN, PRSS1 | EPHX2 1259/4885SIGLEC9 667/4885CYP3A4 3044/4885 |
| US-20040242656-A1 | Serine protease inhibitors | SERPINE1, PRSS1, SERPINB1 | EPHX2 1576/4885SIGLEC9 925/4885CYP3A4 2553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.